

## Redox Buffering of Hypochlorous Acid by Thiocyanate in Physiologic Fluids

Michael T. Ashby,\* Amy C. Carlson, and M. Jared Scott

Department of Chemistry and Biochemistry, University of Oklahoma, 620 Parrington Oval,  
Norman, Oklahoma 73019


Received October 9, 2004; E-mail: mashby@ou.edu

Neutrophils, which comprise 33–75% of all leukocytes in humans, possess an impressive armory of oxidative and non-oxidative mechanisms for combating microorganisms. The oxidative defense mechanism of neutrophils is based upon NADPH oxidase and myeloperoxidase (MPO). The NADPH oxidase system reduces molecular oxygen to generate reactive oxygen species (ROS), including  $\text{H}_2\text{O}_2$ . In the presence of  $\text{H}_2\text{O}_2$ , MPO is capable of oxidizing all of the halides (except  $\text{F}^-$ ), as well as the pseudohalide thiocyanate ( $\text{SCN}^-$ ), to produce hypohalites that are many orders of magnitude more cytotoxic than  $\text{H}_2\text{O}_2$  itself. Hypohalites, and in particular hypochlorous acid ( $\text{HOCl}$ ), appear to play a pivotal role in inflammation.<sup>1</sup> When unchecked, neutrophil-induced inflammation results in local tissue damage, and MPO has been linked to numerous chronic diseases, such as atherosclerosis,<sup>2</sup> cystic fibrosis,<sup>3</sup> and periodontitis.<sup>4</sup> Since  $\text{HOCl}$  is an indiscriminant oxidant, whereas hypothiocyanite ( $\text{OSCN}^-$ ) is not lethal to mammalian cells,<sup>5–9</sup> considerable attention has focused on the substrate selectivity of MPO.<sup>10,11</sup> We demonstrate here that  $\text{HOCl}$  is capable of rapidly oxidizing  $\text{SCN}^-$  to give  $\text{OSCN}^-$ . Thus, the nonenzymic transfer of oxidizing equivalents from  $\text{HOCl}$  to  $\text{SCN}^-$  substantiates the hypothesis that  $\text{SCN}^-$  can serve the role of a redox buffer, thereby governing the lifetime of the more powerful oxidant  $\text{HOCl}$  and its potential for host self-destruction.

MPO is in the ferric form in its resting state. Rapid reaction with  $\text{H}_2\text{O}_2$  produces compound I (MPO–I), which is two oxidizing equivalents above MPO:



The substrate specificities of MPO are determined by the rates of reaction of MPO–I with  $\text{X}^-$ .<sup>12</sup> Because of the relative abundance of halides, it is often suggested that the chief substrate of MPO in blood plasma is  $\text{Cl}^-$ , and that the  $\text{HOCl}$  which is produced is responsible for the cytotoxic capacity of the MPO system.<sup>13</sup> However, we observe that the nonenzymic rate of oxidation of  $\text{SCN}^-$  by  $\text{HOCl}$  to give hypothiocyanite ( $\text{OSCN}^-$ ) is nearly diffusion-controlled,<sup>14</sup> thus suggesting that the major hypohalite produced by MPO in the absence of efficient reductants is  $\text{OSCN}^-$ :




The rate of the reaction of  $\text{HOCl}$  and  $\text{SCN}^-$  (eq 4) is too fast at physiologic pH to measure by stopped-flow. However, the equilibrium of eq 3 is driven to  $\text{OCl}^-$  under basic conditions ( $\text{p}K_a(\text{HOCl}) = 7.4$ ), thus sufficiently slowing reaction 4 to facilitate measurement. Single-mixing stopped-flow reactions of  $\text{HOCl}$  with excess

$\text{SCN}^-$  (i.e., pseudo-first-order conditions) yield traces at 300 nm (near  $\lambda_{\text{max}}$  for  $\text{OCl}^-$ ) that fit single-exponential kinetics models between  $500 \mu\text{M} < [\text{OH}^-] < 1.03 \text{ M}$ , thus suggesting first-order dependence on  $[\text{OCl}^-]$ . The reaction rates were also first-order with respect to  $1/[\text{OH}^-]_0$  (i.e., first-order with respect to  $[\text{H}^+]$ ) over three decades of change in  $[\text{OH}^-]$  (Figure 1) and first-order with respect to  $[\text{SCN}^-]$  (Supporting Information). Production of  $\text{OSCN}^-$  as the primary oxidation product was indicated by an increase in absorbance at 240 nm and further confirmed by employing a double-mixing stopped-flow sequence to convert the product to  $(\text{SCN})_2$  via comproportionation of  $\text{OSCN}^-$  and  $\text{SCN}^-$  (Supporting Information).<sup>15</sup> These data are consistent with a facile proton equilibrium to generate  $\text{HOCl}$  (eq 3), followed by a rate-limiting reaction (eq 4) of  $\text{HOCl}$  with  $\text{SCN}^-$  to yield  $\text{OSCN}^-$  ( $k_3 = 2.34(9) \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ ). Considering only this reaction, we estimate at mean concentrations of  $\text{SCN}^-$  that are found in saliva (1–3 mM) and plasma (20–120  $\mu\text{M}$ ), the half-life of  $\text{HOCl}$  cannot be more than ca. 15  $\mu\text{s}$  and 400  $\mu\text{s}$ , respectively.


While the preceding discussion of the half-lives of  $\text{HOCl}$  in a medium that contains  $\text{SCN}^-$  is illuminative, it does not address the issue of steady-state concentrations of  $\text{HOCl}$  in physiologic fluids, nor the potential physiological consequences of eq 4. To broach these topics, it is necessary to consider dynamic models. Such models can be developed because all of the rate constants<sup>11</sup> for eqs 1–4 have been measured by us and others.<sup>16,17</sup> Although it is not our intention in this Communication to provide a complete model for the redox buffering of  $\text{HOCl}$  by  $\text{SCN}^-$ , Figure 2 illustrates the consequence of the  $k_3$  pathway for a relatively low concentration of MPO (1  $\mu\text{M}$ ) and a high concentration of  $\text{H}_2\text{O}_2$  (1 mM), conditions that are conceivable for extracellular MPO during a respiratory burst. The initial rates of reaction of MPO–I with  $\text{X}^-$  determine the relative amount of the two hypohalites that are initially formed (not illustrated on the time-scale of Figure 2):

$$\% \text{X}^- = \frac{k_2^- [\text{X}^-]}{k_2^{\text{Cl}^-} [\text{Cl}^-] + k_2^{\text{SCN}^-} [\text{SCN}^-]} \quad (5)$$

which equals 72%  $\text{OCl}^-$  and 28%  $\text{SCN}^-$  for typical blood plasma concentrations ( $[\text{Cl}^-]_0 = 100 \text{ mM}$  and  $[\text{SCN}^-]_0 = 100 \mu\text{M}$ ).<sup>18</sup> However, the relative amounts of these hypo(pseudo)halites change as the  $\text{HOCl}$  that is produced in eq 2 reacts with  $\text{SCN}^-$  via eq 4. The concentration–time traces of Figure 2 were computed using rate equations that were programmed into Mathematica. The simultaneous differential equations were solved by numerical methods since the complexity of the equations forbids the development of closed solutions (Supporting Information). No assumptions were made to simplify the rate laws except that the Brønsted acid–base chemistry is facile with respect to all other kinetic processes, and that the concentration of  $\text{Cl}^-$  was assumed to remain constant by virtue of its high concentration. Dynamic changes in concentration were taken into consideration for all other species. Note that



**Figure 1.** Plot of  $k_{\text{eff}}$  ( $[\text{SCN}^-]_0 = 10 \text{ mM}$ ,  $[\text{OCl}^-]_0 = 0.1 \text{ mM}$ ,  $\mu = 1$ ) as a function of  $[\text{OH}^-]^{-1}$  illustrating first-order dependence. The data are fit to the linear function:  $k_{\text{eff}} = (9.85 \times 10^{-2} \text{ M s}^{-1})/[\text{OH}^-] + 1.27 \times 10^{-2} \text{ s}^{-1}$ .



**Figure 2.** Concentration–time curves for HOCl (solid line) and  $\text{OSCN}^-$  (dashed line), with and without consideration of the  $k_3$  pathway.

in reality, such high concentrations of  $\text{H}_2\text{O}_2$  would deactivate MPO on the millisecond time scale by formation of halide-inactive compound II.<sup>19</sup> Nonetheless, Figure 2 clearly illustrates the redox-buffering effect of  $\text{SCN}^-$ ; substantial quantities of HOCl are not produced until the complete oxidation of  $\text{SCN}^-$ . Figure 2 also illustrates another significant aspect of the  $k_3$  pathway, an increase in the rate of production of  $\text{OSCN}^-$  over that from the  $k_2$  pathway alone. Whether this increased rate via the  $k_3$  pathway has physiological consequence remains to be demonstrated.

We propose that the relative amounts of HOCl and  $\text{OSCN}^-$  that are produced in vivo are not dictated by enzyme substrate selectivities alone but rather by kinetic competition between the rate of reaction of HOCl with  $\text{SCN}^-$  and other reductants. While physiologic fluids are very complicated and we cannot expect to accurately predict a priori whether the reaction of  $\text{SCN}^-$  with HOCl is competitive in vivo, we can begin to probe this issue because normal reference values are known for plasma components,<sup>20</sup> and the rate constants for reaction of many of these species with HOCl are available.<sup>21</sup> When the low molecular weight components of human blood plasma are taken into consideration, assuming these species are in excess with respect to HOCl and partitioning is dictated by initial rates, we arrive at the remarkable conclusion that  $\text{SCN}^-$  would consume nearly all available HOCl (Table 1 and Supporting Information). However, there are many macromolecular components of plasma that are likely to compete effectively for HOCl. For example, human serum albumin (HSA) is the main protein component of plasma with a normal concentration range

**Table 1.** Predicted Partitioning of HOCl in Human Blood Plasma by the Components of the Low MW Fraction that are Expected to Exhibit a Significant Rate of Reaction

component	concn (M)	$k_3'$ ( $\text{M}^{-1} \text{s}^{-1}$ ) <sup>a</sup>	% HOCl
Cys	$3 \times 10^{-7}$	$3 \times 10^7$	0.05%
Met	$5 \times 10^{-8}$	$4 \times 10^7$	0.01%
His	$2 \times 10^{-5}$	$1 \times 10^5$	0.01%
Lys	$4 \times 10^{-5}$	$5 \times 10^3$	<0.01%
Trp	$2 \times 10^{-5}$	$1 \times 10^4$	<0.01%
AA	$7 \times 10^{-8}$	$2 \times 10^6$	<0.01%
taurine	$7 \times 10^{-8}$	$5 \times 10^5$	<0.01%
$\text{SCN}^-$	$1 \times 10^{-3}$	$2 \times 10^7$	99.93%

<sup>a</sup> Value  $k_3'$  is defined in eq 4 where  $\text{SCN}^-$  is replaced with the component.

of 35–55 g/L (about 750  $\mu\text{M}$ ). HSA bears HOCl reactive groups (e.g., 12 Met, 2 Cys, 67 S-S).

Experiments are underway to explore the competitiveness of the various components of blood plasma with respect to  $\text{SCN}^-$ .

It has been previously suggested that the  $\text{SCN}^-$  reaction pathway of MPO might serve as a means of ameliorating self-destruction by the more powerful reactant HOCl by acting as a redox buffer, but no specific theories were advanced that explained how the enzyme might regulate the two substrate pathways.<sup>16</sup> The nonenzymic transfer of the oxidizing equivalents of HOCl to  $\text{SCN}^-$  that are described here serves such a role by governing the lifetime of the more powerful oxidant, thereby moderating the potential autotoxicity of HOCl. Furthermore, the oxidizing equivalents of HOCl are preserved in  $\text{OSCN}^-$ , a more discriminate<sup>22</sup> biocide that is not lethal to mammalian cells.

**Acknowledgment.** We are grateful to the PRF (35088-AC3) and the OCAST (HR02-019) for their financial support.

**Supporting Information Available:** Experimental details. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- (1) Hereafter, "HOCl" refers to the equilibrium mixture of HOCl and  $\text{OCl}^-$ , about 1:1 at pH = 7.4.
- (2) Podrez, E. A.; Abu-Soud, H. M.; Hazen, S. L. *Free Radical Biol. Med.* **2000**, *28*, 1717–1725.
- (3) Conese, M.; Copreni, E.; Di Gioia, S.; De Rinaldis, P.; Fumarulo, R. *J. Cystic Fibrosis* **2003**, *2*, 129–135.
- (4) Altman, L. C.; Baker, C.; Fleckman, P.; Luchtel, D.; Oda, D. *J. Periodontal Res.* **1992**, *27*, 70–79.
- (5) Carlsson, J.; Edlund, M. B.; Haenstroem, L. *Infect. Immun.* **1984**, *44*, 581–586.
- (6) White, W. E., Jr.; Pruitt, K. M.; Mansson-Rahemtulla, B. *Antimicrob. Agents Chemother.* **1983**, *23*, 267–272.
- (7) Bjoerck, L.; Claesson, O. *J. Dairy Sci.* **1980**, *63*, 919–922.
- (8) Marshall, V. M.; Reiter, B. J. *Gen. Microbiol.* **1980**, *120*, 513–516.
- (9) Carlsson, J. *J. Oral Path.* **1987**, *16*, 412–416.
- (10) van Dalen, C. J.; Whitehouse, M. W.; Winterbourn, C. C.; Kettle, A. J. *Biochem. J.* **1997**, *327*, 487–492.
- (11)  $k_1 = 2.3 \times 10^7 \text{ M}^{-1} \text{s}^{-1}$ ,  $k^{-1} = 58 \text{ s}^{-1}$ ,  $k_2(\text{Cl}^-) = 2.5 \times 10^4 \text{ M}^{-1} \text{s}^{-1}$ ,  $k_2(\text{SCN}^-) = 9.7 \times 10^6 \text{ M}^{-1} \text{s}^{-1}$ ,  $K_a = 4.0 \times 10^{-8} \text{ M}$ ,  $k_3 = 2.3 \times 10^7 \text{ M}^{-1} \text{s}^{-1}$ .
- (12) Rate =  $k_2[\text{MPO-I}][\text{X}^-]$ .
- (13) Roos, D.; Winterbourn, C. C. *Science* **2002**, *296*, 669–671.
- (14) The bimolecular rate constant for a diffusion-controlled reaction of two uncharged particles in water is about  $8 \times 10^9 \text{ M}^{-1} \text{s}^{-1}$ .
- (15) Barnett, J. J.; Stanbury, D. M. *Inorg. Chem.* **2002**, *41*, 164–166.
- (16) Furtmueller, P. G.; Burner, U.; Obinger, C. *Biochemistry* **1998**, *37*, 17923–17930.
- (17) Furtmueller, P. G.; Obinger, C.; Hsuanyu, Y.; Dunford, H. B. *Eur. J. Biochem. (FEBS)* **2000**, *267*, 5858–5864 and references therein.
- (18) This result is consistent with previous separate rate measurements of MPO-catalyzed oxidation of  $\text{Cl}^-$  and  $\text{SCN}^-$  and the observation that combined solutions of  $\text{Cl}^-$  and  $\text{SCN}^-$  exhibit rates for loss of  $\text{H}_2\text{O}_2$  that are simply the weighted average of the individual rates for  $\text{Cl}^-$  and  $\text{SCN}^-$  for similar concentrations (ref 10).
- (19) Jantschko, W.; Furtmueller, P. G.; Zederbauer, M.; Lanz, M.; Jakopitsch, C.; Obinger, C. *Biochem. Biophys. Res. Commun.* **2003**, *312*, 292–298.
- (20) Duh, S.-H.; Cook, J. D. In *Laboratory Reference Values*, 27th ed.; McDonough, J. T., Ed.; Williams & Wilkins: Baltimore, MD, 2000; pp 2074–2090.
- (21) Pattison, D. I.; Davies, M. J. *Chem. Res. Toxicol.* **2001**, *14*, 1453–1464.
- (22) Ashby, M. T.; Aneetha, H. *J. Am. Chem. Soc.* **2004**, *126*, 10216–10217.

JA0438361